Document Detail

Cell therapy for neuropathic pain in spinal cord injuries.
MedLine Citation:
PMID:  15571449     Owner:  NLM     Status:  MEDLINE    
Cell therapy to treat neuropathic pain after spinal cord injury (SCI) is in its infancy. However, the development of cellular strategies that would replace or be used as an adjunct to existing pharmacological treatments for neuropathic pain have progressed tremendously over the past 20 years. The earliest cell therapy studies for pain relief tested adrenal chromaffin cells from rat or bovine sources, placed in the subarachnoid space, near the spinal cord pain- processing pathways. These grafts functioned as cellular minipumps, secreting a cocktail of antinociceptive agents around the spinal cord for peripheral nerve injury, inflammatory or arthritic pain. These initial animal, and later clinical, studies suggested that the spinal intrathecal space was a safe and accessible location for the placement of cell grafts. However, one major problem was the lack of a homogeneous, expandable cell source to supply the antinociceptive agents. Cell lines that can be reversibly immortalised are the next phase for the development of a practical, homogenous cell source. These technologies have been modelled with a variety of murine cell lines, derived from embryonic adrenal medulla or CNS brainstem, in which cells are transplanted, which downregulate their proliferative, oncogenic phenotype either before or after transplant. An alternative approach for existing human cell lines is the use of neural or adrenal precursors, in which the antinociceptive properties are induced by in vitro treatment with molecules that move the cells to an irreversible neural or chromaffin, and non-oncogenic, phenotype. Although such human cell lines are at an early stage of investigation, their clinical antinociceptive potential is significant given the daunting problem of difficult-to-treat neuropathic SCI pain.
Mary Eaton
Related Documents :
7620899 - Müller cell survival and proliferation in response to medium conditioned by the retina...
12185849 - Initiating and guiding migration: lessons from border cells.
3817299 - Behavior of neural crest cells on embryonic basal laminae.
3148919 - Tyrosinase protein is expressed also in some neural crest derived cells which are not m...
11814109 - Subretinally transplanted embryonic stem cells rescue photoreceptor cells from degenera...
18280109 - Extraction of visual motion and optic flow.
21140179 - Fabrication and growth mechanism of zno nanostructures and their cytotoxic effect on hu...
25139619 - Celastrol induces unfolded protein response-dependent cell death in head and neck cancer.
12644019 - Cycling b-cll cells are highly susceptible to inhibition of the proteasome: involvement...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  4     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-12-01     Completed Date:  2006-04-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1861-9     Citation Subset:  IM    
University of Miami School of Medicine, The Miami Project to Cure Paralysis, 1095 NW 14th Terrace (R-48), Miami, FL 33136, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Line
Cell Transplantation / methods*,  statistics & numerical data
Chromaffin Cells / transplantation
Pain / etiology,  pathology,  surgery*
Pain Measurement / methods
Spinal Cord Injuries / complications,  pathology,  surgery*
Tissue Therapy / methods,  statistics & numerical data

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Injectable cartilage tissue engineering.
Next Document:  Myoblast transplantation for inherited myopathies: a clinical approach.